Thermofield, Inc.

Surgery, chemotherapy (CT) and radiation therapy (RT) are the three main pillars of oncology. Hyperthermia is quickly emerging as the new 4th modality in cancer therapy. Over 30 years of clinical research offers irrefutable proof that adding heat to standard protocols improves tumor control and increases survival for patients with recurrent or inoperable malignancies.

Cancer is the leading cause of death in the US and Europe and it is reaching epidemic proportions in the developing world. The World Health Organization estimates that over 18M new cases will be diagnosed in developing countries by the year 2030. Millions of people worldwide do not have access to radiation or other forms of palliative cancer therapy, leaving many to suffer long and painful deaths.

Tumors tend to reside in a microenvironment that is acidic and hypoxic, making them naturally resistant to standard treatments. Heating a tumor, just a few degrees above normal body temperature (108-113°F), alters these conditions, making it up to 5-times more vulnerable to CT and RT. The Thermofield 250A is a noninvasive, point-of-care technology, used to heat superficial tumors. Thermofield treatments combined with low-cost generic platinum CT can provide cancer patients with a noninvasive alternative to surgery and toxic RT. The technology is less costly than standard treatments and can be easily implemented in hospitals and clinics in developing nations.

Company’s Keywords:

cancer hyperthermia treatment, pain management, veterinary cancer treatment